Rituximab is a chimeric monoclonal antibody directed at the CD20 molecule on the surfaces of some but not all B cells. It depletes almost all peripheral B cells, but other niches of B cells are variably depleted, including synovium.
methotrexate, and those with an incomplete response to tumor necrosis factor inhibitors.
The need for a concomitant traditional disease-modifying drug, the optimal dose of rituximab, and the optimal interval for retreatment remain somewhat uncertain.
Rituximab seems to be most efficacious in seropositive patients and those with an incomplete response to only one tumor necrosis factor inhibitor. Rituximab has a reasonable safety profile, with a small risk of serious infectious events, which is stable over time and repeat courses. congestive heart failure, pregnancy, and hypogammaglobulinemia is imperative.
Vaccinations should be administered prior to treatment whenever possible. Rituximab has been a significant addition to the rheumatologists' armamentarium for the treatment of RA.
INTRODUCTION
Rituximab remains a unique therapeutic option for the treatment of rheumatoid arthritis. There is now a rich literature regarding its efficacy and safety. Questions remain, however, about its exact mechanism of action in RA, the most appropriate dosing schedule, and which RA patients might benefit the most from its use. All of these aspects of rituximab for RA are reviewed in this article.
MECHANISMS OF ACTION
Rituximab is a monoclonal antibody directed at the CD20 molecule on the surfaces of some B be mediated via B cell antigen presentation ability, B cell production of cytokines, and B cell production of autoantibodies such as rheumatoid factor [1, 2] .
Compliance with Ethical Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. Given the data cited from the DANCER, SERENE, and IMAGE trials, there has been controversy over the optimal rituximab dose.
APPROVAL
While it appeared that the 2 9 1000 mg and 2 9 500 mg doses may be equivalent with respect to improvement in signs and symptoms, the 2 9 1000 mg dose showed better ''high hurdle'' outcomes. The 2 9 1000 mg rituximab dose demonstrated a more rapid inhibition of radiographic damage compared to the lower dose, and there was also a trend for more radiographic inhibition with the higher dose. To date, there are no data concerning the ability of the 2 9 500 mg dose to inhibit radiographic progression in 
RETREATMENT WITH RITUXIMAB
In clinical trials (SERENE, MIRROR, DANCER), repeat rituximab dosing was allowed every 6 months [9-11]. Typical clinical responses from rituximab are usually seen 3-4 months after the initial infusions, although the concomitant corticosteroids may provide a very early, transient effect [7] . The duration of the effect is quite variable, so the optimal timing for retreatment is difficult to predict. Repopulation of B cells after rituximab usually requires 6-9 months, but is also variable [1, 4] .
The US package insert for rituximab suggests that rituximab can be given not sooner than every 4 months according to clinical evaluation. Several retreatment options have been studied.
A review of retreated patients from the clinical trials suggested that the fixed-interval (24 week) treat to target strategy was superior to one which retreated patients at the discretion of the physician (prn) [44] . In this retrospective pooled analysis, baseline disease characteristics were thought to be generally well balanced, but those patients receiving prn retreatment were more likely to have established RA with a median 8.5 years of disease and were more likely to be TNF-inadequate responders, while those patients retreated using a treat to target approach were more likely to have a shorter disease duration with a median of 3.6 years of disease and to be biologic-naïve. That the differences between the two groups may have influenced the results remains a significant possibility. A prospective study demonstrated that rituximab retreatment was deemed necessary at around 8 months [45] . The latest European consensus statement suggests that retreatment in initial responders should be considered at 24 weeks in patients who do not achieve low disease activity or remission, and that it should be delayed otherwise until disease activity flares [7] .
Whether or not initial nonresponders should be retreated remains somewhat uncertain [46, 47] . While data from the SUNRISE study demonstrated a low response overall to repeat treatment in initial rituximab nonresponders, repeat treatment was superior to a single course [14] . Analysis of data from the MIRROR study demonstrated that 46% of patients failing to achieve an ACR20 response after initial treatment achieved at least an ACR20 response at 48 weeks following their second treatment course [11] . In the analysis by Vital et al., a proportion of the patients not responding to an initial rituximab course exhibited improvement following an additional course [46] . These data suggest that an additional course of treatment within 24 weeks might be carefully considered in initial rituximab nonresponders, in contrast to the published guidelines which state that alternative treatment agents should probably be considered in initial nonresponders [7] . patient-years) and the general RA population (11.5 patient-years).
SAFETY OF RITUXIMAB
Another paper reported three cases of TB and five cases of non-TB mycobacterial infections in a survey of rituximab-treated RA patients [53] . A previously mentioned report included patients with TB treated with rituximab without reactivation [49] . A recent study of 56 rituximab-treated patients at high risk for TB did not report any reactivation [54] . [7] . Given the relative paucity of PML cases in RA despite the increasing numbers of patients receiving rituximab in surveillance databases, the concern regarding PML may be waning.
The risk of malignancy does not appear to be increased in the clinical trials with very small numbers of cases, although patients with a known previous malignancy are usually excluded and the trials are of relatively short duration. In the pooled analysis, rituximab was not associated with an increased risk of any malignancy when compared to age-and sex-matched standard incidence ratios [51] .
The calculated incidence rate of any malignancy was 0.69/100 patient-years. The most common solid malignancy was breast cancer. In addition, there was no evidence of an increased risk of malignancy with cumulative exposure to rituximab. Other reviews have also not found an increase in malignancies [60, 61] .
A French registry review also reported no significant increase in malignancies in a rituximab-treated RA patient cohort [62] . A recent comparative effectiveness study comparing the potential risk of cancer across biologic and non-biologic DMARDs reported that the risk of any cancer with rituximab was similar to that with methotrexate [63] . In a recent abstract, the German registry reported that RA patients with a history of lymphoma, solid malignancies, or skin cancer do not have higher rates of recurrence when treated with rituximab in comparison to non-biologic DMARDs [64] .
With regards to cardiovascular risk, which is increased in patients with RA regardless of treatment, myocardial infarction was the most frequent cardiovascular event reported in the pooled analysis of long-term safety data [47] . The event rate was 0.41/100 patient-years compared to 0.27/100 patient-years in the MTX ? placebo-treated patients. This rate was similar to that reported in other RA patients treated with DMARDS and TNFi [65, 66] . The risk of stroke was similar in both groups and also similar to other published data [67] . This premedication is now part of the approval for each cycle of rituximab, although whether or not it is required for all late cycles has not been determined [7] . The routine use of antihistamines and/or paracetamol is not required, but may be useful for mild IRR [7] .
Although rituximab does not affect [51] . No increases in overall infection rates were observed in patients during or after the development of low IgM or IgG levels, but for IgG these rates were higher than in patients who never developed a low IgG. With the small numbers of patients with low IgG levels, no placebo comparator, and difficulties determining when immunoglobulin levels decreased, analysis of the data was thought to be limited [51] 
ANTI-RITUXIMAB ANTIBODIES
In the randomized, controlled trials, the incidence of human anti-chimeric antibodies (HACA) varied from 2.7% to 7.1% [9] [10] [11] [12] [13] [14] [15] . In the pooled analysis of long-term rituximab safety, 11% of rituximab-treated patients were found to have HACAs during at least one visit [51] . These and other studies have found no relationship between HACA and the dose of rituximab administered, any specific clinical manifestations, the ability to deplete B cells, the frequency of infusion reactions, the clinical efficacy of the initial dosing, or the efficacy of retreatment [51, 68, 69] .
Biologic DMARD Therapy Post-Rituximab
In a study concerning patients in whom an insufficient response was obtained with rituximab, switching from rituximab to a TNFi was relatively safe and not associated with an increase in infections [70] . In this study, the TNFi were initiated at least 4 months after rituximab, and the rate of serious infections was similar to that expected when TNFi are initiated in biologic-naïve DMARD RA patients.
Similarly, the pooled analysis of long-term rituximab safety data concluded that the use of subsequent biologics was not associated with an increase in the serious infection rate [51] .
Other Treatment Considerations
Given all of these safety concerns, prior to initiating rituximab in RA patients, a careful medical history and physical examination should be undertaken to determine potential contraindications. Some of these include hypersensitivity to murine proteins, serious active infection, significant congestive heart failure, and pregnancy [7] . In addition to routine laboratory testing, baseline immunoglobulin levels should be measured, since low IgG levels are associated with a higher risk of infection, and the use of rituximab in patients with existing hypogammaglobulinemia should be considered with caution or avoided [7] .
Hepatitis B and C serologies should be undertaken, because reactivation of hepatitis B surface Ag negative but hepatitis B core Ab positive disease has been rarely reported [71, 72] . Patients who have been treated with TNFi should have previously been evaluated for TB, but due to the observation that there is no evidence for an increased frequency of TB in RA patients treated with rituximab, screening patients for tuberculosis is not currently thought to be necessary [7] .
Vaccinations in RA patients should be considered before rituximab, including pneumococcal, influenza, tetanus toxoid, and hepatitis B, and these are recommended at least 4 weeks before the initiation of rituximab [7] .
Diminished humoral responses to influenza and pneumococcus have been reported in RA patients on rituximab ? methotrexate, so immunization while on rituximab therapy may not be effective [73] [74] [75] . Live vaccines are not recommended.
Lastly, as currently recommended, rituximab infusion requires 4.25 h for the initial infusion and 3.25 h for subsequent infusions. This regimen is based on the rituximab usage in non-Hodgkins lymphoma, where the incidence of IRR is much higher than that observed in RA [76] . Long infusion times and frequent infusion rate changes are not only inconvenient but increase infusion center costs. Several studies have attempted to increase the rate of rituximab infusion after the initial infusion, with reported success [76] [77] [78] [79] [80] . In a recent study, infusion over 2 h was well tolerated and not associated with an increased rate of IRR [76] . Rapid infusion protocols, however, require further testing before general acceptance will be achieved.
CONCLUSION
Rituximab has been a significant addition to the shortlist of biologic agents approved for the treatment of RA. It has a unique mechanism of action, it has been established as relatively safe, and the details regarding screening, dosing, and follow-up are becoming better understood.
Rituximab is an important option for selected RA patients, and is most effective in those who are seropositive and have been exposed to one TNFi. As with all biologics for RA, further information regarding the safety of rituximab over longer periods of time will be critical. Future studies will hopefully determine exactly where rituximab will be placed in the evolving treatment paradigm for rheumatoid arthritis. 
